Metabolic drug interactions with newer antipsychotics: A comparative review

Basic and Clinical Pharmacology and Toxicology

Volumn 100, Issue 1, 2007, Pages 4-22

  Spina, Edoardo ^a,c   De Leon, Jose ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b Eastern State Hospital   (United States)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENYTOIN; QUETIAPINE; REBOXETINE; RISPERIDONE; SERTINDOLE; SERTRALINE; THIORIDAZINE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; AKATHISIA; ANXIETY; ATAXIA; BIOTRANSFORMATION; BIPOLAR DISORDER; BLOOD LEVEL; BLOOD TOXICITY; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONFUSION; CONSCIOUSNESS DISORDER; DELIRIUM; DEPRESSION; DISORIENTATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; GRAND MAL SEIZURE; GRAPEFRUIT JUICE; GYNECOMASTIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDUCED HYPOTENSION; LETHARGY; MONOTHERAPY; MYOCLONUS SEIZURE; NAUSEA; NEUROTOXICITY; OXIDATION; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RESPIRATORY ARREST; SCHIZOPHRENIA; SEDATION; SEIZURE; SHORT SURVEY; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION; URINE RETENTION;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; DRUG INTERACTIONS; DRUG TOXICITY; HUMANS;

EID: 33845988396     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00017.x     Document Type: Short Survey

References (197)

1. Stahl S. Essential Psychopharmacology of Antipsychotics and Mood Stabilizers. Cambridge University Press, Cambridge, UK, 2002.
2. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19 (Suppl 1):1-93.
3. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005;19:91-103.
4. Jeste DV, Dolder CR. Treatment of non-schizophrenic disorders: focus on atypical antipsychotics. J Psychiatr Res 2004;38:73-103.
5. Spina E, Scordo MG. Newer antipsychotics: comparative review of drug interactions. Expert Rev Neurother 2001;1:171-82.
6. Prior TI, Baker GR. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003;28:99- 112.
7. de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005;46:262-73.
8. Guengerich FP. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 1997;106:161-82.
9. Nelson DR, Koymans L, Kamataki T et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
10. Meyer UA. The molecular basis of genetic polymorphism of drug metabolism. J Pharm Pharmacol 1994;46 (Suppl 1):409-15.
11. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413-580.
12. Liston HL, Markowitz JS, Devane L. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 2001;21:500-15.
13. Mackenzie PI, Owens IS, Burchell B et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997;7:255-69.
14. de Leon J. Glucuronidation enzyme genes and psychiatry. Int J Neuropsychopharmacol 2003;6:57-72.
15. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90.
16. Thummel KE, Kunze KL, Shen DD. Metabolically-based drug-drug interactions: principles and mechanisms. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds). Metabolic Drug Interactions. Lippincott Williams & Wilkins, Philadelphia, PA, 2000;3-19.
17. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
18. Nielsen TL, Rasmussen BB, Flinois JP, Beaune P, Brosen K. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 1999;289:31-7.
19. Armstrong SC, Cozza KL, Sandson NB. Six patterns of drugdrug interactions. Psychosomatics 2003;44:255-8.
20. Sproule BA, Naranjo CA, Bremner KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997;33:454-71.
21. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C19, CYP2C10, CYP2D6, and CYP3A. Br J Clin Pharmacol 1996;41:181-6.
22. Shin JG, Soukhova N, Flockart DA. Effect of antipsychotic drugs on human liver cytochrome P450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 1999;27:1078-84.
23. Mulsant BH, Foglia JP, Sweet RA, Rosen J, Lo KH, Pollock BJ. The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J Clin Psychopharmacol 1997;17:318-21.
24. Prior TI, Chue PS, Tibbo P, Baker GR. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999;9:301-9.
25. Caccia S. New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. Curr Opin Invest Drugs 2002;3:1073-80.
26. Raggi MA, Mandrioli R, Sabbioni C, Pucci V. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological implications. Curr Med Chem 2004;11:279-96.
27. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 2006;58:871-5.
28. Bertilsson L, Carrillo JA, Dahl ML et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
29. Dahl ML, Llerena A, Bondesson U, Lindstrom L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994;37:71-4.
30. Eierman B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44:439-46.
31. Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997;25:1379-82.
32. Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001;41:823-32.
33. Huang ML, van Peer A, Woestenborghs R et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.
34. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4. Naunyn Schmiederbergs Arch Pharmacol 1999;359:147-51.
35. Yasui-Furukori N, Hidestrand M, Spina E, Facciolà G, Scordo MG, Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001;29:1263-8.
36. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-93.
37. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol 2002;17:233-8.
38. Devane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine. Clin Pharmacokinet 2001;40:509-22.
39. Murdoch D, Keating GM. Sertindole: a review of its use in schizophrenia. CNS Drugs 2006;20:233-55.
40. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000;49 (Suppl 1):35S-42S.
41. Swainston-Harrison T, Perry C. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715-36.
42. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 2002;17:1-13.
43. Boulton DW, Devane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinità for atypical and conventional antipsychotics. Life Sci 2002;71:163-9.
44. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, Devane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporte P-glycoprotein. Psychopharmacology 2006;187:415-23.
45. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, Devane CL. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 2004;7:415-9.
46. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997;17:194-201.
47. Spina E, Avenoso A, Facciolà G et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 2001;153:238-43.
48. Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 1997;32:93-100.
49. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, Christodoulou GN. Toxic interaction between risperidone and clozapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:407-9.
50. Koreen AR, Lieberman JA, Kronig M, Cooper TB. Cross-tapering clozapine and risperidone. Am J Psychiatry 1995;152:1690.
51. Tyson SC, Devane CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 1995;152:1401-2.
52. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-7.
53. Raaska K, Raitasuo V, Neuvonen PJ. Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration. Eur J Clin Pharmacol 2002;58:587-91.
54. Potkin SG, Thyrum PT, Alva G et al. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002;22:121-30.
55. Smith T, Risken J. Effect of clozapine on plasma nortriptyline concentration. Pharmacopsychiatry 1994;27:41-2.
56. Spina E, Scordo M, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003;17:517-38.
57. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
58. Brosen K, Skielbo E, Rasmussen BB, Poulson HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
59. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995;40:481-5.
60. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996;36:792-8.
61. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylaton. Br J Clin Pharmacol 1997;44:495-8.
62. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Flood JG. Serum concentrations of clozapine and its metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994;151:123-5.
63. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996;153:820-3.
64. Spina E, Avenoso A, Facciolà G et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998;13:141-5.
65. McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ. Evaluation of time-dependent cytochrome P450 inhibitionusing cultured human hepatocytes. Drug Metab Dispos 2006;34:1291-300.
66. Bork J, Rogers T, Wedlund P, de Leon J. A pilot study of risperidone metabolism: the role of cytochrome P450 2D6 and 3A. J Clin Psychiatry 1999;60:469-76.
67. Spina E, Avenoso A, Scordo MG et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002;22:419-23.
68. Benazzi F. Gynecomastia with risperidone-fluoxetine combination. Pharmacopsychiatry 1999;32:41.
69. Bozikas V, Petrikis P, Karavatos A. Urinary retention caused after fluoxetine-risperidone combination. J Psychopharmacol 2001;15:142-3.
70. Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychiatric patients. Pharmacopsychiatry 2002;35:50-6.
71. Gossen D, de Suray JM, Vandenhanden F, Onkelinx C, Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002;4:1-6.
72. Potkin SG, Thyrum PT, Alva G et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002;22:174-82.
73. Spina E, Avenoso A, Salemi M et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000;33:213-7.
74. Wetzel H, Anghelescu I, Szegedi A et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18:2-9.
75. Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia A. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 2001;23:223-7.
76. Barnhill J, Susce MT, Diaz FJ, de Leon J. Risperidone half-life in a patient taking paroxetine: a case report. Pharmacopsychiatry 2005;38:223-5.
77. Saito M, Yasui-Furukori N, Nakagami T, Furukori H, Kaneko S. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol 2005;25:527-32.
78. Hiemke C, Weighmann H, Hartter S, Dahmen N, Wetzel H, Muller H. Elevated serum levels of clozapine after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
79. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
80. Dequardo JM, Roberts M. Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 1996;153:840-1.
81. Dumortier G, Lochu A, Colen de Melo P et al. Elevated clozapine plasma concentrations after fluvoxamine initiation. Am J Psychiatry 1996;153:738-89.
82. Koponen HJ, Leinonen E, Lepola U. Fluvoxamine increases the serum clozapine levels significantly. Eur Neuropsychopharmacol 1996;6:69-71.
83. Szegedi A, Anghelescu I, Wiesner J et al. Addition of low-dose of fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999;32:148-53.
84. Fabrazzo M, La Pia S, Monteleone P et al. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. J Clin Psychopharmacol 2000;20:708-10.
85. Kuo FJ, Lane HY, Chang WH. Extrapyramidal symptoms after addition of fluvoxamine to clozapine. J Clin Psychopharmacol 1998;18:483-4.
86. Shader RI, Greenblatt DJ. Clozapine and fluvoxamine, a curious complexity. J Clin Psychopharmacol 1998;18:101-2.
87. Olesen OV, Linnet K. Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000;20:35-42.
88. Szegedi A, Wiesner J, Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 1995;15:141-3.
89. Lammers CH, Deuschle M, Weigmann H et al. Coadministration of clozapine and fluvoxamine in psychotic patients: clinical experience. Pharmacopsychiatry 1999;2:76-7.
90. Weigmann H, Gerek S, Zeisig A, Muller M, Hartter S, Hiemke C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001;23:410-3.
91. de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L. Interaction of olanzapine with fluvoxamine. Psychopharmacology 2001;155:219-20.
92. Hiemke C, Avi P, Jabarin M et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 2002;22:502-6.
93. D'Arrigo C, Migliardi G, Santoro V et al. Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacol Res 2005;52:497-501.
94. Reeves RR, Mack JE, Beddingfield JJ. Neurotoxic syndrome associated with risperidone and fluvoxamine. Ann Pharmacother 2002;36:440-3.
95. Chong SA, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J. Clin Psychopharmacol 1997;17:68-9.
96. Pinninti NR, de Leon J. Interaction of sertraline with clozapine. J Clin Psychopharmacol 1997;17:119-20.
97. Spina E, D'Arrigo C, Migliardi G et al. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit 2004;26:386- 90.
98. Taylor D, Ellison Z, Ementon Shaw L, Wickham H, Murray R. Co-administration of citalopram and clozapine: effect on plasma clozapine levels. Int Clin Psychopharmacol 1998;13:19-21.
99. Avenoso A, Facciolà G, Scordo MG et al. No effect of citalopram on plasma concentrations of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia. Clin Drug Invest 1998;16:393-8.
100. Borba C, Henderson D. Citalopram and clozapine: potential drug interaction. J Clin Psychiatry 2000;61:301-2.
101. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol 1999;39:297-309.
102. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 1996;41:339-43.
103. Khan A, Preskorn S. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. J Clin Psychiatry 2001;62:375-6.
104. Taylor D, Bodani M, Hubbeling A, Murray R. The effect of nefazodone on clozapine plasma concentrations. Int Clin Psychopharmacol 1999;14:185-7.
105. Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Levita A. No effect of reboxetine on plasma concentrations of clozapine, risperidone and their active metabolites. Ther Drug Monit 2001;23:675-8.
106. Zoccali R, Muscatello MR, La Torre D et al. Lack of pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res 2003;48:411-4.
107. Klimke A, Klieser E. Sudden death after intravenous application of lorazepam in a patient treated with clozapine. Am J Psychiatry 1994;151:780.
108. Besag FMC, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf 2006;29:95-118.
109. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002;43 (Suppl 2):37-44.
110. Junghan U, Albers M, Woggon B. Increased risk of hematological side-effect in psychiatric patients treated with clozapine and carbamazepine? Pharmacopsychiatry 1993;26:262.
111. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995;28:26-8.
112. de Leon J, Bork J. Risperidone and cytochrome P4503A. J Clin Psychiatry 1997;58:450.
113. Spina E, Avenoso A, Facciolà G et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000;22:481-5.
114. Ono S, Mihara K, Suzuki A et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology 2002;162:50-4.
115. Spina E, Scordo MG, Avenoso A, Perucca E. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. J Clin Psychopharmacol 2001;21:108-9.
116. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanisms. Eur J Clin Pharmacol 1998;54:639-43.
117. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999;21:87-90.
118. Licht RW, Olesen OV, Friis P, Laustsen T. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine. J Clin Psychopharmacol 2000;20:110-2.
119. Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit 2002;24:512-7.
120. Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 2002;24:518-26.
121. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2005;61:58-69.
122. Fitzgerald B, Okos A. Elevation of carbamazepine-10, 11-epoxide by quetiapine. Pharmacotherapy 2002;22:1500-3.
123. Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 2000;49 (Suppl 1):65S-70S.
124. Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994;36:487-8.
125. Costello L, Suppes TA. A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol 1995;15:139-40.
126. Longo LP, Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine. Am J Psychiatry 1995;152:650.
127. Facciolà G, Avenoso A, Scordo MG et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit 1999;21:341-5.
128. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003;25:46-53.
129. Aichhorn W, Marksteiner J, Walch T, Zernig G, Saria A, Kemmler G. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006;21:81-5.
130. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005;45:89-93.
131. Facciolà G, Avenoso A, Spina E, Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit 1998;20:628-30.
132. Lane HY, Su KP, Chang WH, Jann MW. Elevated plasma clozapine concentrations after phenobarbital discontinuation. J Clin Psychiatry 1998;59:131-3.
133. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991;52:23-5.
134. Wong YWJ, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 2001;21:89-93.
135. Reimers A, Skogvoll E, Kutschera Sund J, Spigset O. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol 2005;25:342-8.
136. Sidhu J, Job S, Bullman J et al. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol 2006;61:420-6.
137. Kossen M, Selten JP, Kahn RS. Elevated clozapine plasma level with lamotrigine. Am J Psychiatry 2001;158:1930.
138. Bienentreu SD, Kronmuller KTH. Increase in risperidone plasma level with lamotrigine. Am J Psychiatry 2005;162:811-2.
139. Castberg I, Spigset O. Risperidone and lamotrigine: no evidence of a drug interaction. J Clin Psychiatry 2006;67:1159.
140. Tiihonen J, Hallikainen T, Ryynanen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003;54:1241-8.
141. Spina E, D'Arrigo C, Migliardi G et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit 2006;28:599-602.
142. Jann MW, Hon YY, Shamsi SA, Zheng J, Awad EA, Spratlin V. Lack of pharmacokinetic interactions between lamotrigine and olanzapine in healthy volunteers. Pharmacotherapy 2006;26:627-33.
143. Muscatello MR, Pacetti M, Cacciola M et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia 2005;46:771-4.
144. Tiihonen J, Halonen P, Wahlbeck K et al. Topiramate add-on in treatment-resistant schizophrenia; a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005;66:1012-5.
145. Migliardi G, D'Arrigo C, Santoro V et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone and quetiapine in patients with psychotic disorders. Clin Neuropharmacol (in press).
146. Magnuson TM, Keller BK, Burke WJ. Extrapyramidal side effects in a patient treated wit risperidone plus donepezil. Am J Psychiatry 1998;155:1457-9.
147. Liu HC, Lin SK, Sung SM. Extrapyramidal side-effect due to drug combination of risperidone and donepezil. Psychiatry Clin Neurosci 2002;56:479.
148. Zhao Q, Xie C, Pesco-Koplowitz L, Jia X, Parier JL. Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil. J Clin Pharmacol 2003;43:180-6.
149. Reyes JF, Preskorn SH, Khan A et al. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol 2004;58 (Suppl 1):50-7.
150. Weiser M, Rotmensch HH, Korczyn AD, Hartman R, Cicin-Sain A, Anand R. A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Int J Geriatr Psychiatry 2002;17:343-6.
151. Huang F, Lasseter KC, Janssens L, Verhaeghe T, Lau H, Zhao Q. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. J Clin Pharmacol 2002;42:1341-51.
152. Farren CK, Famedi FA, Rosen ME, Woods S, Jatlow P, Kosten TR. Significant interaction between clozapine and cocaine in cocaine addicts. Drug Alcohol Depend 2000;59:153-63.
153. Bano MD, Mico JA, Agujetas M, Lopez ML, Guillen JL. Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients: interaction with plasma levels. Actas Esp Psiquiatr 2001;29:215-20.
154. Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 in vivo and in vitro. Antimicrob Agents Chemother 1992;36:942-8.
155. Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 2000;56:585-9.
156. Markowitz JS, Devane CL. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentrations. J Clin Psychopharmacol 1999;19:289-91.
157. Letsas K, Sideris A, Kounas SP, Efremidis M, Korantzoupoulos P, Kardaras F. Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol 2005;109:273-4.
158. Yamazaki H, Shimada T. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos 1998;26:1053-7.
159. Funderburg LG, Vertrees JE, True JE, Miller AL. Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry 1994;151:1840-1.
160. Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC. Erythromycin-induced clozapine toxic reaction. Arch Intern Med 1996;156:675-7.
161. Hagg S, Spigset O, Mjorndal T, Granberg K, Persbo-Lundqvist G, Dahlqvist R. Absence of interaction between erythromycin and a single dose of clozapine. Eur J Clin Pharmacol 1999;55:221-6.
162. Li KY, Li X, Cheng ZN, Zhang BK, Peng WX, Li HD. Effects of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia. Eur J Clin Pharmacol 2005;60:791-5.
163. Wong SL, Cao G, Mack RJ, Granneman GR. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol 1997;37:1056-61.
164. Reinach B, de Sousa G, Dostert P, Ings R, Gugenheim J, Rahmani R. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact 1999;121:37-48.
165. Joos AAB, Frank UG, Kaschka WP. Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection. J Clin Psychopharmacol 1998;18:83-5.
166. von Moltke LL, Greenblatt DJ, Schmider J et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antigungal agents. J Clin Pharmacol 1996;36:783-91.
167. Raaska K, Neuvonen PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 1998;54:167-70.
168. Jung SM, Kim KA, Cho HK et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther 2005;78:520-8.
169. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics: a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol 2000;49 (Suppl 1):71S-76S.
170. Kubo M, Koue T, Inaba A et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005;20:55-64.
171. Unadkat JD, Wang Y. Protease inhibitors. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds). Metabolic Drug Interactions. Lippincott Williams & Wilkins, Philadelphia, PA, 2000;647-52.
172. Jover F, Cuadrado JM, Andreu L, Merino J. Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol 2002;25:251-3.
173. Kelly DV, Beique LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 2002;36:827-30.
174. Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol 2002;22:366-70.
175. Rogers T, de Leon J, Atcher D. Possible interaction between warfarin and quetiapine. J Clin Psychopharmacol 1999;19:382-3.
176. Furst BA, Champion KM, Pierre JM, Wirshing DA, Wirshing WC. Possible association of QTc interval prolongation with coadministration of quetiapine and lovastatin. Biol Psychiatry 2002;51:264-5.
177. Giner V, Munoz R, Redon J. Risperidone and severe cerivastatin-induced rhabdomyolysis. J Intern Med 2002;251:177-8.
178. Webber MA, Mahmud W, Lightfoot JD, Shekhar A. Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol 2004;18:432-4.
179. Szymanski S, Lieberman JA, Picou D, Masiar S, Cooper T. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991;52:21-2.
180. Strakowski SM, Kech PE, Wong YWJ, Thyrum PT, Yeh C. The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders. J Clin Psychopharmacol 2002;22:201-5.
181. Wilner KD, Hansen RA, Folger CJ, Geoffrov P. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol 2000;49 (Suppl 1):57S-60S.
182. Frick A, Kopitz J, Bergemann N. Omeprazole reduces clozapine plasma concentrations. A case report. Pharmacopsychiatry 2003;36:121-3.
183. Mookhoek EJ, Loonen AJ. Retrospective evaluation of the effect of omeprazole on clozapine metabolism. Pharm World Sci 2004;26:180-2.
184. Gabbay V, O'Dowd MA, Mamamtavrishvili M, Asnis GM. Clozapine and oral contraceptives: a possible drug interaction. J Clin Psychopharmacol 2002;22:621-2.
185. Zevin S, Benowitz NL. Drug interactions with tabacco smoking: an update. Clin Pharmacokinet 1999;36:425-38.
186. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990;147:1471-5.
187. Hasegawa M, Guiterrez R, Way L, Meltzer HI. Relationship between clinical efficacy and clozapine concentration in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993;13:383-90.
188. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J. Role of smoking-induced cytochrome P450 (CYP) 1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003;23:119-27.
189. de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 2004;55:491-3.
190. McCarthy R. Seizure following smoking cessation in a clozapine responder. Pharmacopsychiatry 1994;27:210-1.
191. Meyer JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 2001;21:569-74.
192. Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2000;49:59-63.
193. Vainer JL, Chouinard G. Interaction between caffeine and clozapine. J Clin Psychopharmacol 1994;14:284-5.
194. Carrillo JA, Herraiz AG, Ramos SI, Benitez J. Effect of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 1998;18:311-6.
195. Raaska K, Raitasuo V, Laitila J, Neuvonen PJ. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol 2004;94:13-8.
196. Vandel S, Netillard C, Perault M, Bel AM. Plasma levels of clozapine and desmethylclozapine are unaffected by concomitant ingestion of grapefruit juice. Eur J Clin Pharmacol 2000;56:347-8.
197. Lane HY, Jann MW, Chang YC et al. Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. J Clin Psychiatry 2001;62:812-7.